All
Faith, Science, and Miracles: A Conversation About CAR-T Cell Therapy with the Whitehead Family
December 4th 2020Emily Whitehead was the first child to receive chimeric antigen receptor (CAR)-T cell therapy. Eight years later, she and her parents discuss her ongoing remission from acute lymphoblastic leukemia.
Cancer, Boundaries, Safety and COVID-19 Considerations During the Holidays
December 4th 2020Figuring out boundaries and safety in relation to COVID-19 has been an ongoing challenge this year, and with the holidays coming up pressure is mounting. Here is how one cancer survivor considered their boundaries this year.
Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma
December 4th 2020Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.
Immunotherapy 101: What Patients Can Expect from CAR-T Cell Therapy
December 3rd 2020Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.
Artificial Intelligence May Accurately Predict Short-Term Mortality in Patients with Cancer
December 3rd 2020An artificial intelligence-based algorithm within the electronic medical record provided real-time and accurate predictions of the short-term mortality rate of patients with cancer, outperforming all other prognostic incidences commonly used.
How the Cancer Care Team is Like a Symphony Orchestra
November 30th 2020Often, patients with cancer will come into contact with only a handful of members of their care team: a primary care physician or oncologist, perhaps a nurse or two. But as Dr. Phillip J. Koo explained, it helps to view the cancer care team – including those who a patient may never see – with a wider lens.